116 related articles for article (PubMed ID: 38205842)
1. Do survivors of borderline ovarian tumors have susceptibility to secondary primary malignancies? A SEER population-based study.
Wang J; Du Y; Kang Y
Int J Gynaecol Obstet; 2024 Jun; 165(3):1229-1236. PubMed ID: 38205842
[TBL] [Abstract][Full Text] [Related]
2. Risk Prediction of Second Primary Malignancies in Primary Early-Stage Ovarian Cancer Survivors: A SEER-Based National Population-Based Cohort Study.
Xu J; Huang C; Wu Z; Xu H; Li J; Chen Y; Wang C; Zhu J; Qin G; Zheng X; Yu Y
Front Oncol; 2022; 12():875489. PubMed ID: 35664751
[TBL] [Abstract][Full Text] [Related]
3. The impact of age at the time of radiotherapy for localized prostate cancer on the development of second primary malignancies.
Krasnow RE; Rodríguez D; Nagle RT; Mossanen M; Kibel AS; Chang SL
Urol Oncol; 2018 Nov; 36(11):500.e11-500.e19. PubMed ID: 30249519
[TBL] [Abstract][Full Text] [Related]
4. Risk of specific types of ovarian cancer after borderline ovarian tumors in Denmark: A nationwide study.
Hannibal CG; Frederiksen K; Vang R; Kurman RJ; Kjaer SK
Int J Cancer; 2020 Aug; 147(4):990-995. PubMed ID: 31930502
[TBL] [Abstract][Full Text] [Related]
5. Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes.
Matsuo K; Machida H; Mandelbaum RS; Grubbs BH; Roman LD; Sood AK; Gershenson DM
Gynecol Oncol; 2019 May; 153(2):230-237. PubMed ID: 30797590
[TBL] [Abstract][Full Text] [Related]
6. Risk of second primary thyroid cancer in cancer survivors.
Yuan Y; Sun P; Xiao H; Li L; Li J; Ai X
Sci Rep; 2024 May; 14(1):12478. PubMed ID: 38816510
[TBL] [Abstract][Full Text] [Related]
7. Second Primary Malignancy Risk in Multiple Myeloma from 1975 to 2018.
Wang J; Lv C; Zhou M; Xu JY; Chen B; Wan Y
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230842
[TBL] [Abstract][Full Text] [Related]
8. Increased incidence of second primary malignancy in patients with malignant astrocytoma: a population-based study.
Wang W
Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31138756
[TBL] [Abstract][Full Text] [Related]
9. Risks of non-ovarian cancers in women with borderline ovarian tumor: a national cohort study in Sweden.
Dobilas A; Jansåker F; Li X; Sundquist K; Borgfeldt C
BMC Cancer; 2023 Oct; 23(1):951. PubMed ID: 37807065
[TBL] [Abstract][Full Text] [Related]
10. Second Primary Malignancies in Patients with Colorectal Cancer: A Population-Based Analysis.
Jia H; Li Q; Yuan J; Sun X; Wu Z
Oncologist; 2020 Apr; 25(4):e644-e650. PubMed ID: 31943509
[TBL] [Abstract][Full Text] [Related]
11. Second Primary Malignancies in Mantle Cell Lymphoma: A US Population-based Study.
Shah BK; Khanal A
Anticancer Res; 2015 Jun; 35(6):3437-40. PubMed ID: 26026107
[TBL] [Abstract][Full Text] [Related]
12. Risk of second primary malignancy after non-small cell lung cancer: a competing risk nomogram based on the SEER database.
Zhou H; Shen J; Zhang Y; Huang Y; Fang W; Yang Y; Hong S; Liu J; Xian W; Zhang Z; Ma Y; Zhou T; Zhao H; Zhang L
Ann Transl Med; 2019 Sep; 7(18):439. PubMed ID: 31700875
[TBL] [Abstract][Full Text] [Related]
13. Incidence and risk outcomes of second primary malignancy of patients with post-operative colorectal cancer.
Yang J; Wu F; An H; Gan H
Int J Colorectal Dis; 2023 Mar; 38(1):88. PubMed ID: 36995483
[TBL] [Abstract][Full Text] [Related]
14. Epidemiological analysis of second primary malignant neoplasms in cancer survivors aged 85 years and older: a SEER data analysis (1975-2016).
Zhao X; Zhang L; Bai L; Zhao Y; Yang Q
Sci Rep; 2022 Jul; 12(1):11688. PubMed ID: 35803964
[TBL] [Abstract][Full Text] [Related]
15. Trends in the risk and burden of second primary malignancy among survivors of smoking-related cancers in the United States.
Adjei Boakye E; Buchanan P; Hinyard L; Osazuwa-Peters N; Simpson MC; Schootman M; Piccirillo JF
Int J Cancer; 2019 Jul; 145(1):143-153. PubMed ID: 30613963
[TBL] [Abstract][Full Text] [Related]
16. Malignancies diagnosed before and after anal squamous cell carcinomas: A SEER registry analysis.
Jani KS; Lu SE; Murphy JD; Romesser PB; Jethwa KR; Li D; Chundury A; Wu AJ; Hathout L; Hallemeier CL; Jabbour SK
Cancer Med; 2021 Jun; 10(11):3575-3583. PubMed ID: 33960690
[TBL] [Abstract][Full Text] [Related]
17. Risk of second primary malignancies in a population-based study of adult patients with essential thrombocythemia.
Shrestha R; Giri S; Pathak R; Bhatt VR
World J Clin Oncol; 2016 Aug; 7(4):324-30. PubMed ID: 27579252
[TBL] [Abstract][Full Text] [Related]
18. The risk and prognosis of secondary primary malignancy in lung cancer: a population-based study.
Hong J; Wei R; Nie C; Leonteva A; Han X; Du X; Wang J; Zhu L; Tian W; Zhou H
Future Oncol; 2021 Nov; 17(33):4497-4509. PubMed ID: 34402680
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study.
Matsuo K; Machida H; Grubbs BH; Matsuzaki S; Klar M; Roman LD; Sood AK; Gershenson DM
Gynecol Oncol; 2020 Apr; 157(1):21-28. PubMed ID: 31954535
[TBL] [Abstract][Full Text] [Related]
20. Borderline ovarian tumors: French guidelines from the CNGOF. Part 2. Surgical management, follow-up, hormone replacement therapy, fertility management and preservation.
Bourdel N; Huchon C; Abdel Wahab C; Azaïs H; Bendifallah S; Bolze PA; Brun JL; Canlorbe G; Chauvet P; Chereau E; Courbiere B; De La Motte Rouge T; Devouassoux-Shisheboran M; Eymerit-Morin C; Fauvet R; Gauroy E; Gauthier T; Grynberg M; Koskas M; Larouzee E; Lecointre L; Levêque J; Margueritte F; D'argent Mathieu E; Nyangoh-Timoh K; Ouldamer L; Raad J; Raimond E; Ramanah R; Rolland L; Rousset P; Rousset-Jablonski C; Thomassin-Naggara I; Uzan C; Zilliox M; Daraï E
J Gynecol Obstet Hum Reprod; 2021 Jan; 50(1):101966. PubMed ID: 33144266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]